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ABSTRACT
Background. Body composition measures may predict
outcomes of cancer surgery. Whereas low muscle mass
shown on preoperative computed tomography (CT) scans
has been associated with worse outcomes after surgery for
pancreatic cancer, less consideration has been given to low
muscle attenuation, reflecting poor muscle quality. Studies
relating muscle mass and muscle attenuation with out-
comes for patients with periampullary, nonpancreatic
cancer are lacking.
Methods. Skeletal muscle mass and attenuation were
assessed in 166 consecutive patients undergoing pancre-
atoduodenectomy (PD) for periampullary, nonpancreatic
cancer at a single center between 2000 and 2012. The
skeletal muscle index (SMI) was calculated from cross-
sectional muscle area on preoperative CT imaging at the
third lumbar vertebra level (L3) and normalized for height.
The skeletal muscle attenuation index (MAI) was calcu-
lated by measuring the average Hounsfield units of the total
muscle area at the L3 level. Overall survival (OS) and the
rate of major postoperative complications (Clavien-Dindo
C3) were extracted from prospectively maintained
databases.
Results. Low SMI was present in 78.3 % and low MAI in
48.8 % of the patients. The multivariate analysis showed
lymph node metastasis [hazard ratio (HR) 1.8; 95 % con-
fidence interval (CI) 1.1–2.9], microscopic radicality (HR
2.0; 95 % CI 1.2–3.4), and low MAI (HR 2.0; 95 % CI
1.2–3.3), but not low SMI to be significantly associated
with decreased OS. Low MAI (HR 1.9; 95 % CI 1.0–3.8)
was the only independent risk factor for major postopera-
tive complications.
Conclusion. Skeletal muscle quality, but not muscle mass,
predicted survival and major complications after PD for
periampullary, nonpancreatic cancer. Preoperative CT-
derived body composition measures may stratify patients
into risk categories and support shared decision making.
Recently, the value of computed tomography (CT)-derived
body composition measures for predicting postoperative
outcomes has gained interest. For example, loss of skeletal
muscle mass shown on preoperative CT imaging has been
associated with worse short- and long-term outcomes after
resection of tumors of varying origin.1 Also in gastrointestinal
and hepato-pancreato-biliary (HPB) surgery,2 including sur-
gery for pancreatic cancer,3–6 low skeletal muscle mass has
been associated with increased morbidity and mortality and
worse survival. Less consideration has been given to muscle
attenuation shown on CT imaging, which has been associated
with worse survival for patients with solid tumors of respira-
tory and gastrointestinal origin, for patients with melanoma or
metastatic renal cell carcinoma,7–9 and recently for patients
with pancreatic cancer.4,5,10
Low muscle attenuation reflects decreased muscle
quality by an accumulation of intramuscular lipid deposi-
tions (myosteatosis), and the presence of myosteatosis on
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preoperative CT imaging may be shown through a negative
correlation with the amount of intramuscular adipose tis-
sue.11–13 Both myosteatosis and loss of muscle mass lead to
a decrease in muscle strength.14
Studies associating preoperative CT-derived body
composition measures of patients having periampullary,
nonpancreatic cancer with survival and major postopera-
tive complications do not exist. However, periampullary
cancer constitutes about one third of all patients undergo-
ing pancreatoduodenectomy (PD).15 The 5-year survival
rate after resection of periampullary (distal bile duct,
papilla, and duodenum) cancer may reach 50 %, twice the
rate for pancreatic cancer patients.15,16 Mortality rates after
PD are about 1 to 3 % in expert centers, but postoperative
morbidity occurs in up to 50 % of patients.15,17 Therefore,
risk stratification and response prediction before treatment
remain of great interest. We assessed the association of
skeletal muscle mass and muscle attenuation (quality) with
OS and major postoperative complications in patients
undergoing PD for periampullary, nonpancreatic cancer.
PATIENTS AND METHODS
Study Cohort and Data Acquisition
All patients who underwent PD between 2000 and 2012
for primary papilla of Vater (C24.1), extrahepatic bile duct
(C24.0), or duodenal (C17.0) adenocarcinoma were selec-
ted from a prospectively maintained database at a single
center. Patients with pancreatic ductal adenocarcinoma
(C25) were excluded. Topography and morphology were
coded according to the international Classification of Dis-
eases for Oncology (ICD-O). The primary outcome was
OS, defined as the time between PD and death. Patients
were observed until death or 1 September 2015, at which
time they were censored. Survival data was obtained from
the Municipal Personal Records Database, the central
registry for all Dutch inhabitants.
The secondary outcome was the rate of major postop-
erative complications, defined as any complication
classified as Clavien-Dindo grade 3 or higher within 30
days after PD or during admission, whichever was
longer.18 Overall morbidity was evaluated and consisted of
surgical and nonsurgical complications. The incidence of
major postoperative pancreatic fistula, postpancreatectomy
hemorrhage, and delayed gastric emptying also were noted,
all according to the International Study Group of Pancre-
atic Surgery definitions.17,19,20
CT Image Analysis
The final preoperative CT scan was used to determine
skeletal muscle mass, muscle attenuation, and adipose tis-
sue area. Patients were excluded from the analysis if no
preoperative CT scan was available for analysis or if the
cross-sectional area of interest was not in the field of view.
Sagittal images of CT scans were selected at the level of
lumbar-3 (L3) from the same contrast series by an expe-
rienced radiologist (C.Y.N.). The third lumbar vertebra
region contains the psoas, paraspinal (erector spinae,
quadratus lumborum), and abdominal wall muscles (ex-
ternal and internal obliques, rectus abdominus, transversus
abdominus).
The images were analyzed by a trained single observer
(N.C.H.) using SliceOmatic V5.0 software (Tomovision,
Montreal, QC, Canada). This software enables specific
tissue demarcation using density thresholds by Hounsfield
units (HU; Fig. 1). The observer was blinded to the
patient’s postoperative course and survival.
To determine skeletal muscle mass at the L3 level, the
cross-sectional skeletal muscle surface (cm2) was identified













FIG. 1 Computed tomography scans at the third lumbar vertebrae
level of two male patients. Right Patient with a low skeletal muscle
index (SMI, 56.8) (muscle mass) but a normal muscle attenuation
index (MAI, 49.8) (muscle quality). Right Patient with a normal SMI
and a low MAI (MAI, 24.0). The skeletal muscle area is highlighted
in red. 1 rectus abdominis, 2 external oblique, 3 internal oblique, 4
transverse abdominal, 5 psoas, 6 paraspinal
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Muscle area was normalized for height in meters squared
(m2) and reported as lumbar skeletal muscle index (SMI)
(cm2/m2). The muscle attenuation index (MAI) was
determined by calculating the average HU at the L3 level.
Intramuscular adipose tissue was additionally identified
and quantified by HU thresholds of –190 to –30.7,13
Statistical Analysis
To determine cutoff values for low SMI and MAI, we
calculated sex-specific cutoff values by optimum stratifi-
cation, as previously described.1,21,22 Optimum
stratification is a statistical method that determines the
threshold value of a continuous variable (SMI, MAI),
which is based on log-rank statistics and best separates
patients in terms of time to an event outcome (death).
Differences between groups were analysed using Pear-
son’s chi-square test and the independent t test as
appropriate. Correlations between continuous variables
were assessed using Pearson’s correlation coefficients. All
p values were considered significant at the 0.05 level.
Survival data are reported as median (range). OS rates,
defined as the months of survival after PD, were calculated
and compared using the Kaplan-Meier method. Conven-
tional covariates included in the univariable survival
analysis next to the dichotomous variables SMI and MAI
were sex, age, American Society of Anesthesiologists
(ASA) grade, tumor category, lymph node metastasis,
tumor size, tumor grade, and resection margin sta-
tus.16,23–27 The conventional covariates included in the
univariate analysis for major postoperative complications
next to SMI and MAI were sex, age, ASA grade, body
mass index (BMI), diabetes mellitus, and tumor location.28
Characteristics with a p value lower than 0.10 in the uni-
variate analysis were entered into multivariable models.
Statistical analyses were performed using IBM SPSS
statistics version 21 (IBM, Armonk, NY, USA).
RESULTS
Study Cohort
The study identified 281 patients. Patients were exclu-
ded when a CT scan was inadequate to determine SMI or
MAI (n = 97, 35 %) or when patient height could not be
retrieved (n = 18, 6 %). Consequently, 166 patients were
analyzed. The baseline characteristics between included
and excluded patients did not differ (Supplementary
Table 1). The baseline characteristics for the patients with
low SMI and normal SMI, and for those with low MAI and
normal SMA are shown in Table 1. Some significant dif-
ferences are observed in the baseline characteristics. The
median interval between the final preoperative CT scan and
the date of surgery was 55 days [interquartile range (IQR),
39–74 days].
The sex-specific cutoff values for low SMI were 53.5
cm2/m2 for males and 46.4 cm2/m2 for females. Low SMI
was present in 130 patients (78 %). The sex-specific cutoff
values for low MAI were 36.3 HU for males and 36.0 HU
for females. Low MAI was present in 81 patients (49 %).
Low MAI was negatively correlated with intramuscular
adipose tissue area (r = –0.65; p\ 0.001).
Overall Survival
The median follow-up period for the patients who were
alive on 1 September 2015 was 71 months. The median
survival time for the patients receiving PD for peri-
ampullary carcinoma was 44 months (range 0–181
months). During the follow-up period, 91 patients (55 %)
died.
The OS curves for the patients with low SMI and normal
SMI and those with low MAI and normal SMI are shown in
Fig. 2. The median OS for the patients with low SMI was
72 months, which did not differ from the median OS of 124
months for the patients with normal SMI (p = 0.28;
Fig. 2a). The median OS for the patients with low MAI
was 39 months, significantly lower than the median OS of
98 months for the patients with normal MAI (p\ 0.001;
Fig. 2b).
Low SMI was not associated with an increased hazard
ratio (HR) of death [HR 1.3; 95 % confidence interval (CI)
0.8–1.2]. Low MAI was associated with an increased
hazard ratio of death (HR 2.4; 95 % CI 1.6–3.8). Other
factors associated with OS in the univariate analysis
included age (HR 1.0; 95 % CI 1.0–1.1), ASA score of 3 or
4 (HR 1.7; 95 % CI 1.0–2.7), T3 tumor stage (HR 2.3;
95 % CI 1.2–4.6), lymph node metastasis (HR 2.5; 95 %
CI 1.6–3.8), and microscopic radicality (HR 2.8; 95 % CI
1.8–4.2).
In the multivariable analysis, low MAI remained inde-
pendently associated with decreased OS (HR 1.95; 95 %
CI 1.2–3.3). The independent predictors of OS also inclu-
ded lymph node metastasis (HR 1.8; 95 % CI 1.1–2.9) and
microscopic radicality (HR 2.0; 95 % CI 1.2–3.4)
(Table 2).
Major Postoperative Complications
The incidence of overall morbidity, major complica-
tions, and International Study Group of Pancreatic Surgery
(ISGPS) complications is compared between patients with
low and normal SMI and patients with low and normal
MAI in Table 3. After PD, the overall morbidity rate was
66.3 % (110 patients). The overall morbidity rate was
similar between the patients with low SMI (66.9 %) and
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those with normal SMI (63.9 %) (p = 0.73). The overall
morbidity was significantly higher for the patients with low
MAI (75.3 %) than for the patients with normal MAI
(57.6 %) (p = 0.02).
The incidence of major complications was 47 % (78
patients). The incidence of major complications was sta-
tistically equal between the patients with low SMI (47.7 %)
and those with normal SMI (44.4 %) (p = 0.73). The
incidence of major complications was significantly higher
for the patients with low MAI (58 %) than for the patients
with normal MAI (36.5 %) (p = 0.005). The patients with
low SMI and those with normal SMI had similar rates for
grades B and C postoperative pancreatic fistula (25.0 vs
29.2 %; p = 0.62), grades B and C postpancreatectomy
hemorrhage (5.6 vs 6.9 %; p = 0.77), and grades B and C
delayed gastric emptying (38.9 vs 37.7 %; p = 0.97). The
patients with low MAI experienced more grade B or C
postpancreatectomy hemorrhage (11.1 vs 2.4 %; p = 0.02)
and more grade B or C delayed gastric emptying (46.9 vs
29.4 %; p = 0.03). The rate for grades B and C postop-
erative pancreatic fistula was similar between the patients
with low and high MAI (32.1 vs 24.7 %; p = 0.29).
Low MAI was associated with an increased hazard ratio
of major postoperative complications (odds ratio [OR] 2.4;
95 % CI 1.3–4.5) but low SMI was not (OR 1.1; 95 % CI
0.5–2.4) . The only other factor associated with major
complications in the univariate analysis was BMI (OR 1.1;
95 % CI 1.0–1.2). After adjustment for potential con-
founding factors, only low MAI retained an independent
association with the occurrence of major postoperative
complications (OR 1.9; 95 % CI 1.0–3.8) (Table 4).
DISCUSSION
In this first study investigating CT-derived body com-
position measures in patients undergoing PD for
periampullary, nonpancreatic cancer, low muscle quality,
but not low muscle mass, was independently associated
with decreased survival and an increased incidence of
major postoperative complications.
Various well-established patient and tumor characteris-
tics are known to affect short- and long-term postoperative
outcomes for patients with pancreatic and periampullary
cancer.16,23–26 Our study adds to the previously identified
risk factors for these patients, with a prognostic value
equalling that of other conventional covariates.
The recent international interest in CT-derived body
composition measures has led to identification of muscle
mass and muscle quality as new independent predictors of
outcome, with growing evidence to validate their prog-
nostic impact.2 After some very recent studies investigating
pancreatic cancer,3–6,10 our study is a first step toward
determining the use of preoperative CT-derived body
composition measures to stratify all patients receiving PD
for cancer into risk categories and to assist in shared
decision making.
Ideally, treatment of low muscle quality would lead to
improved postoperative outcomes. Unfortunately, no such
treatment is currently available.1 A randomized controlled
trial with 52 nonsurgical, elderly patients demonstrated the
clear effects of moderate physical exercise on age-related
decline in muscle strength, but it involved a 12-month
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FIG. 2 Overall survival rates after pancreatoduodenectomy for
periampullary, nonpancreatic cancer according to a skeletal muscle
index and b skeletal muscle attenuation
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therefore has no relevance in the preoperative setting or
during neoadjuvant treatment. However, several prehabil-
itation strategies consisting of physical exercise have
demonstrated improved postoperative outcomes.30 The
effect of preoperative muscle or total-body exercises on
postoperative outcomes for patients with low muscle mass
or low muscle quality should be subject to future
investigation.
Until recently, very little research on skeletal muscle
attenuation (quality) was conducted. Some recent studies
have investigated the prognostic significance of low muscle
attenuation for patients with pancreatic cancer.4,5,10 One
study included 230 patients undergoing PD, distal
pancreatectomy, or total pancreatectomy for pancreatic
ductal adenocarcinoma and identified muscle attenuation as
an independent predictor of both worse survival and
recurrence-free survival.4 In another study of 104 pancre-
atoduodenectomies, skeletal muscle attenuation was an
independent predictor of severe complications according to
the National Surgical Quality Improvement Program
(NSQIP).5 It was not described whether periampullary
cancer in the final pathology diagnosis was included in this
study. Recently, attenuation of the psoas muscle on pre-
operative CT scan also was identified as an independent
predictor of 1-year mortality for 518 elderly patients
receiving HPB surgery, including pancreatic resection.10 In




HR 95 % CI p value HR 95 % CI p value
Female sex 62 0.70 0.46–1.05 0.09 0.71 0.46–1.10 0.13
Age (cont.) 166 1.03 1.01–1.05 0.003 1.01 0.98–1.03 0.52
ASA score 3–4 32 1.65 1.01–2.71 0.05 1.22 0.73–2.05 0.45
Tumor category
T1 Ref – Ref
T2 1.22 0.58–2.58 0.60 0.85 0.39–1.83 0.68
T3 2.34 1.18–4.64 0.02 1.21 0.57–2.59 0.63
T4 2.12 0.88–5.13 0.10 0.89 0.34–2.32 0.80
Lymph node metastasisa 2.48 1.63–3.77 \0.001 1.82 1.14–2.91 0.01
Tumor size 1.03 0.92–1.15 0.58
Tumor grade
Well differentiated 8 Ref –
Moderately differentiated 90 1.57 0.49–5.09 0.45 1.29 0.37–4.47 0.69
Poorly differentiated 68 2.75 0.85–8.91 0.09 1.80 0.52–6.21 0.35
Microscopic irradicality (R1) 49 2.75 1.80–4.23 \0.001 2.01 1.20–3.36 0.01
Low SMI 130 1.33 0.79–1.24 0.28
Low MAI 81 2.44 1.58–3.77 \0.001 1.95 1.16–3.29 0.01
HR hazard ratio, CI confidence interval, cont. continuous, ASA American Society of Aaesthesiologists, R1 positive margin, SMI skeletal muscle
mass index, MAI muscle attenuation index
a There were no patients with distant metastasis
TABLE 3 Complications after 166 pancreatoduodenectomies for periampullary, nonpancreatic cancer
Normal SMI
(n = 36) n (%)
Low SMI
(n = 130) n (%)
p value Normal MAI
(n = 85) n (%)
Low MAI
(n = 81) n (%)
p value
Overall morbidity 23 (63.9 %) 87 (66.9 %) 0.73 49 (57.6 %) 61 (75.3 %) 0.02
Major complicationa 16 (44.4 %) 62 (47.7 %) 0.73 31 (36.5 %) 47 (58.0) 0.005
Postoperative fistula grades B & C 9 (25 %) 38 (29.2 %) 0.62 21 (24.7 %) 26 (32.1 %) 0.29
Postpancreatectomy hemorrhage grades B & C 2 (5.6 %) 9 (6.9 %) 0.77 2 (2.4 %) 9 (11.1 %) 0.02
Delayed gastric emptying grades B & C 14 (38.9 %) 49 (37.7 %) 0.97 25 (29.4 %) 38 (46.9 %) 0.03
SMI skeletal muscle mass index, MAI muscle attenuation index
a Clavien-Dindo grade 3 or higher complication
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the limited number of studies available, skeletal muscle
quality was an important covariate in the prognosis of
patients receiving PD for cancer.
Previous studies have identified muscle mass as an
independent predictor of postoperative complications and
survival and also after resection of pancreatic cancer.1–6 In
one of the earlier, large series after resection of pancreatic
adenocarcinoma, muscle mass was not associated with the
risk of overall morbidity or serious complications but was
associated with an increased risk of 3-year mortality.3 To
our surprise, we did not find an association between muscle
mass and postoperative major complications or survival in
the univariate analysis. It is unlikely that the influence of
muscle mass on postoperative outcomes is different after
resection of periampullary cancer compared with pancre-
atic cancer, although the incidence of complications does
differ between the two groups.28,31,32 It is unclear whether
the unequal distribution of patients between low muscle
mass (78 %) and normal muscle mass (22 %) could be a
reason for this finding.
We used the preferred and accepted method (optimal
stratification) to find the most significant cutoff for L3
muscle index, as previously described.1,21 We found dif-
ferent cutoffs for men and women, which suggests that
other, ‘‘static’’ cutoffs do not suit our cohort, so we believe
that using these cutoffs would lead to inaccurate effect
measurement. However, also when other previously used
cutoff values for low muscle mass were applied, muscle
mass still showed no effect on survival.2 The patients were
better distributed among the muscle quality categories (51
vs 49 %). This suggests that some patients had a low
muscle mass, but with normal muscle quality.
We found a significant negative correlation between
MAI and intramuscular adipose tissue on preoperative CT
scan, which reflects an accumulation of intramuscular lipid
content.11–13 A higher muscle lipid content has been related
to loss of muscle strength.14 This may explain why muscle
quality and not muscle mass was an independent predictor
of survival and major postoperative complications.
Complications after pancreatic surgery are very com-
mon.17,19,20 After resection for periampullary cancer,
complications may occur even more frequently than after
resection for pancreatic adenocarcinoma.28,31,32 The inci-
dence of overall and major morbidity did not differ
between the patients with low and normal muscle mass.
The patients with low muscle quality experienced overall
and major complications more frequently than the patients
with normal muscle quality. These findings are reflected in
our identification of low muscle quality as an independent
predictor of survival and major complications.
We used several of the strongest and most frequent
covariates predicting postoperative outcomes after pan-
creatic cancer surgery.16,23–26 Unfortunately, the presence
of perineural or perivascular invasion was documented
only incidentally by the pathologist and could therefore not
be incorporated into our analysis.
We found a relatively long interval (median 55 days)
between the final preoperative CT scan and the date of
surgery. Possibly, as patients are referred to our tertiary
hospital including CT scan, the interval is increased due to
first discussion of the patient within a multidisciplinary
team meeting, after which the operation is planned. Find-
ings have shown that scans performed at a longer interval
before surgery increases the incidence of intraoperative





OR 95 % CI p value OR 95 % CI p value
Female sex 62 0.99 0.53–1.85 0.97
Age (cont.) 166 1.02 0.99–1.05 0.12
ASA score 3–4 32 0.85 0.39–1.85 0.68
BMI (kg/m2) (cont.) 166 1.10 1.01–1.20 0.03 1.07 0.98–1.17 0.13
Diabetes mellitus 25 0.87 0.37–2.04 0.75
Tumor location
Ampulla 83 Ref –
Distal bile duct 65 0.91 0.47–1.74 0.77
Duodenum 18 1.41 0.51–3.93 0.51
Low SMI 130 1.14 0.54–2.39 0.73
Low MAI 81 2.41 1.29–4.50 0.006 1.93 1.01–3.77 0.049
OR odds ratio, CI confidence interval, cont. continuous, ASA American Society of Anesthesiologists, BMI body mass index, SMI skeletal muscle
mass index, MAI muscle attenuation index
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metastatic disease.33 Patient and event numbers were
unfortunately too small to determine whether results would
be different if patients who had a scan performed more than
30 days before the surgery were excluded.
This study had some limitations. We had to exclude a
relatively high number of patients due to inadequacy of CT
scans. However, the baseline characteristics did not differ
significantly between the included and excluded patients
(Supplementary Table 1). Furthermore, we identified some
differences in baseline characteristics, mainly, a lower R1
rate for the patients with a low muscle mass and a higher
BMI for the patients with low muscle attenuation than for
the other patients. However, we corrected for these and
other possible confounders in our analyses. Finally, we
included three periampullary cancer types in our cohort.
Survival and the incidence of complications may differ
between the three types of periampullary tumors (duode-
num, papilla, and distal bile duct tumors).16,28 However, in
the sensitivity analysis, including also the cancer type in
the multivariable analyses did not influence survival or the
rate of major complications (data not shown).
CONCLUSION
In a large cohort of patients undergoing PD for peri-
ampullary, nonpancreatic cancer, low muscle quality, but
not low muscle mass, predicted poor survival and major
postoperative complications. Preoperative CT scans con-
tain valuable information on patient body composition that
may improve preoperative risk assessment and can support
shared decision making.
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